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Abstract: Carbapenem-resistant Acinetobacter baumannii (CR-Ab) infections are associated with
high morbidity and mortality. The aim of the study was to evaluate the in-vitro activity of
different antimicrobial combinations (with and without colistin, COL) against clinical isolates of
CR-Ab collected from patients with CR-Ab infection, including unconventional combinations such
as COL + VANcomycin (VAN) and COL + rifampin (RIF). CR-Ab strains were collected from
hospitalized patients at Sapienza University of Rome. Antimicrobial susceptibility patterns were
determined throughout MIC50/90s whereas the synergistic activity was evaluated by qualitative (i.e.,
checkerboard) and quantitative (i.e., killing studies) methods. All the strains were found oxacillinase
(OXA) producers and tigecycline (TIG) sensitive whereas 2 strains were resistant to COL. Application
of the checkerboard method indicated complete synergism in COL combinations at different extension:
21.4%, 57.1%, 42.8%, 35.7% for COL + meropenem (MEM), COL + RIF, COL + VAN and COL + TIG,
respectively, with the non-conventional combinations COL + VAN and COL + RIF exhibiting the
highest rate of synergism. Regarding COL-free combination, complete synergism was observed in
35.7% of the strains for MEM + TIG. Killing studies showed that the combinations COL + MEM,
COL + TIG and MEM + TIG were bactericidal and synergistic against both colistin-sensitive and low
colistin-resistant strains whereas only the combinations COL + VAN and COL + RIF showed an early
and durable bactericidal activity against all the tested strains, with absence of growth at 24 h. This
study demonstrated that COL-based combinations lead to a high level of synergic and bactericidal
activity, especially COL + VAN and COL + RIF, even in the presence of high level of COL resistance.
Keywords: carbapenem-resistant A. baumannii; colistin; vancomycin; antimicrobial combinations;
synergy; time-kill studies
1. Introduction
The rapid spread of multidrug-resistant bacteria (MDR) such as carbapenem-resistant (CR)
Enterobacteriaceae (CR-E), CR Acinetobacter baumannii (CR-Ab) and MDR Pseudomonas aeruginosa
(MDR-Pa) has become a public health concern, especially in some countries where the diffusion
of carbapenem-resistant microorganisms is nowadays endemic [1,2]. In particular, CR-Ab represents a
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major challenge for physicians due to the high mortality rates especially in the ICU and its capability
to persist in the environment [3–5].
Therapeutic options are severely limited [2,6] and are mainly based on colistin-containing
combinations. However, the ability of CR-Ab to acquire resistance even to colistin (COL) further
limits, if not completely precludes, the therapeutic choices. In this scary scenario, the lack of activity
of new antimicrobials nowadays available in many countries imposes new efforts in finding the best
therapeutic approach against this pathogen [7]. Furthermore, although in the pipeline there are several
promising agents with activity towards all CR microorganisms including CR-Ab (i.e., cefiderocol),
they are still in in early clinical development of and will be eventually available only in the coming
years [8].
Polymyxins at the moment are the antimicrobials with the greatest level of in-vitro activity against
CR-Ab [9]. In the studies evaluating the synergistic activity of COL-containing combinations, results
suggested that COL plus carbapenems or COL plus antimicrobials active only against Gram-positive
bacteria, such as vancomycin (VAN) and rifampin (RIF) can be considered the most active in-vitro
combinations [10–12].
However, the potential survival benefit obtained with combination therapy instead of
monotherapy in infections caused by CR-Ab is still debated, following a recent randomized clinical trial
resulted with no advantages of COL combined with meropenem (MEM) versus COL monotherapy for
severe CR-Ab infections [13]. On the other hand, the use of COL-based combination (i.e., COL plus RIF)
gave a higher rate of microbiological eradication compared with that obtained using monotherapy [14],
furthermore, the most likely possibility of developing resistance during COL monotherapy should be
taken into account, possibly contributing to the rationale for combination use in CR-Ab infections.
Apart from resistance, which has been increasingly reported in the last years [15], the use of
COL in the clinical practice might be limited by its toxic effect; therefore, developing alternative and
effective COL-free combinations are of prime importance [16].
Based on the above mentioned studies, the aim of the research reported herein was to evaluate the
in-vitro activity of antimicrobial combinations with and without COL against clinical strains of CR-Ab
with different clonal types, with particular emphasis on the non-conventional regimens containing
COL plus VAN or RIF. In addition, clinical and demographic data of patients were evaluated.
2. Results
2.1. Bacterial Strains and Clinical Data Collection
Overall, 14 patients with CR-Ab infection (3 bloodstream infections; 2 skin and soft tissue infection;
9 hospital-acquired pneumonia) were included in the study. Clinical characteristics and outcomes of
patients are shown in Table 1. All the patients received colistin-based combinations [10: COL + high
dosage (i.e., 6 grams/d) of MEM; 2: COL +TIG; 2: COL + RIF], with a total of 6/14 (43%) also receiving
VAN. The overall clinical cure was 12/14 (85.7%). CR-Ab strains were isolated from upper/lower
respiratory tract fluids (n = 9), blood (n = 3) and purulent drainages (n = 2).
2.2. Molecular Typing by Pulsed-Field Gel Electrophoresis
Pulsed-field gel electrophoresis (PFGE) analysis was reliable in 13 out of the 14 CR-Ab isolated
strains. Overall, 5 clones were detected: A, B, C, D, E (Figure 1). Among these, clone B was the most
common (n = 4) and was found exclusively in the SUR Paediatric Intensive Care Unit (PICU) whereas
clone C was detected in only one strain isolated from a patient hospitalized in a different Intensive
Care Unit before being transferred to SUR hospital. Clones A, D and E were found in isolated patients
hospitalized in different wards of the hospital (i.e., Internal Medicine, Gerontology and Pneumology).
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Table 1. Clinical characteristics of patients (n = 14) with CR-Ab infection.
Patient Type of Infection Therapy Duration of Therapy (days) Outcome
1 BSI C + M + V 14 Cured
2 HAP C + M + V 13 Cured
3 SSI C + T + V 30 Cured
4 SSI C + R 14 Cured
5 BSI C + M 30 Cured
6 HAP C + V + R 14 Cured
7 BSI C + M + V 6 Died*
8 HAP C + M 17 Cured
9 HAP C + M 14 Cured
10 HAP C + M 14 Cured
11 HAP C + M 14 Cured
12 HAP C + T 14 Cured
13 HAP C + M 10 Died*
14 HAP C + M + V 14 Cured
BSI: Bloodstream infection. SSI: Skin and Soft Tissue Infection. HAP: Hospital-acquired pneumonia. *: pt#7 died
because of CR-Ab infection; pt#13 died for reason other than CR-Ab infection. C: colistin; M: meropenem; V:
vancomycin; R: rifampin; T: tigecycline.
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14 (E). Isolates with more than 3 fragment variations were assumed to represent strains with major 
Figure 1. ApaI ulse-field gel electrophoresis ( ) patterns of A baumannii. Lanes 1, 15 contain
molecular size patterns (lambda ladder). Lanes 2,3 (PFGE pattern A), 4–7 (B), 8 (C), 9–11 (D) and
12–14 (E). Isolates with more than 3 fragment variations were assumed to represent strains with major
patterns (assignment of capital letters), while isolates with 1–3 fragment differences were considered
subtypes (capital letters with numerical subscripts).
2.3. Antimicrobial Activity
Throughout the VITEK-2 system, all the strains were carbapenem-resistant (MIC > 16mg/L)
whereas Table 2 summarizes the in-vitro susceptibility of CR-Ab throughout MBD and E-test methods.
Throughout MBD, MICs50/90 were 128/256 mg/L for MEM, 64/128 mg/L for VAN, 256/512 mg/L
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for GEN, 0.5/1 mg/L for TIG, 0.5/2 mg/L for COL and 16/512 mg/L for RIF. In particular, 2 strains
were resistant to COL [1 with low-level of resistance (COL-LR, MIC 4 mg/L), 1 with high-level of
resistance (COL-HR, MIC 256 mg/L)]. All the strains were oxacillinase (OXA) producers.
Table 2. In-vitro susceptibility of carbapenem-resistant Acinetobacter baumannii (CR-Ab) throughout
macrobroth dilution (MBD) and E-test methods.
Antibiotic MEM COL VAN RIF GEN TIG
Method MBD MBD E-Test MBD MBD MBD E-Test MBD
Patients/
Clinical
Isolates
1 128 1.000 0.750 256 8 4 2.00 0.50
2 256 0.250 0.300 32 4 >512 1.50 1.00
3 256 0.060 0.380 64 >512 2 0.75 1.00
4 128 0.032 0.075 128 >512 >512 2.00 0.50
5 32 0.125 0.380 64 4 >512 1.00 1.00
6 128 4.000 4.00 64 4 512 3.00 0.50
7 512 0.015 0.750 128 >512 >512 2.00 1.00
8 256 0.030 0.380 128 4 32 1.50 0.25
9 256 0.250 0.500 128 4 >512 2.00 0.50
10 32 2.000 1.000 128 2 >512 1.50 0.50
11 128 0.500 1.500 64 16 64 0.75 0.75
12 8 256.0 128.0 32 >512 2 1.00 0.25
13 64 0.125 0.500 32 4 >512 1.50 0.25
14 32 0.500 0.500 64 4 256 2.00 0.50
MEM: meropenem; COL: colistin; VAN: vancomycin; RIF: rifampin; GEN: gentamicin; TIG: tigecycline.
Complete synergism was observed in 3 out of 14 (21.4%), 8 out of 14 (57.1%), 6 out of 14 (42.8%)
and 5 out of 14 (35.7%) strains using combinations COL + MEM, COL + RIF, COL + VAN and COL +
TIG, respectively. Among COL-free combinations, MEM + TIG showed complete synergism in 5/14
(35.7%) (Table 3).
Table 3. Synergism of different combinations against CR-Ab throughout checkerboard method. The 14
clinical isolated as listed in Table 1 were used.
Strains PFGEPattern
COL + MEM COL + RIF COL + VAN COL + TIG MEM + TIG
FICI◦ Syn FICI Syn FICI Syn FICI Syn FICI Syn
1 B 0.375 S 0.375 S 0.250 S 0.375 S 1.000 I
2 B1 0.625 I 0.375 S 0.625 I 1.000 I 0.500 S
3 B 0.625 I 0.625 I 0.750 I 0.625 I 0.375 S
4 A 0.750 I 0.625 I 0.625 I 1.000 I 0.750 I
5 D 0.625 I 0.500 S 0.250 S 0.250 S 0.625 I
6 * C 0.250 S 0.250 S 0.250 ◦ S 0.250 S 0.375 S
7 A1 1.000 I 1.000 I 1.000 I 2.000 I 0.625 I
8 E1 0.625 I 0.750 I 0.375 S 2.000 I 1.000 I
9 B2 0.750 I 0.750 I 0.625 I 2.000 I 0.250 S
10 E 0.250 S 0.250 S 0.250 S 0.250 S 0.625 I
11 - 1.000 I 0.250 S 0.375 S 0.375 S 0.375 S
12 ** D2 0.750 I 0.250 S 0.625 § I 2.000 I 1.000 I
13 D1 2.000 I 0.625 I 0.625 I 2.000 I 0.625 I
14 E1 0.625 I 0.250 S 0.625 I 0.750 I 0.625 I
Total n 3/14 8/14 6/14 5/14 5/14
Total (%) 21.4 57.1 42.8 35.7 35.7
*: strain with low-level of COL-resistance (COL-LR, MIC 4 mg/L); **: strain with high-level of COL-resistance
(COL-HR, MIC 256 mg/L); ◦: FICI 0.250 was obtained at the following concentrations: 0.5 mcg/mL COL
(0.125 × MIC)+ 8 mcg/mL VAN (0.125 × MIC); §: FICI 0.625 was obtained at the following concentrations:
32 mcg/mL COL (0.125 × MIC) + 16 mcg/mL VAN (0.5 × MIC). The fractional inhibitory concentration index
(FICI) of each combination was defined as: ∑FIC: FICA + FICB = MICA + B/MICAalone + MICB + A/MICBalone.
Synergism was defined as FICI ≤ 0.5 (S) whereas FICI > 0.5 but <4 were considered as indifferent (I). COL: colistin;
MEM: meropenem; RIF: rifampin; VAN: vancomycin; TIG: tigecycline.
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In killing studies, monotherapy showed a significant growth at 24 h in both colistin-sensitive
and colistin-resistant strains. With regard to colistin-based combinations, COL + MEM and COL +
TIG were bactericidal and synergistic against both colistin-sensitive and low colistin-resistant strains
whereas only the combinations COL + VAN and COL + RIF showed an early and durable bactericidal
activity against all the tested strains (including the high colistin-resistant one), with absence of growth
at 24h (Figure 2A–C). On the other hand, the combination MEM + TIG showed a bactericidal and
synergistic activity at 24 h at the concentrations 1 × MIC MEM + 1 × MIC TIG and 0.5 × MIC MEM
+ 0.5 × MIC TIG for the colistin-sensitive and the low-level of colistin-resistance strains whereas no
effect at all was observed for the high-level of colistin-resistance strain (Figure 3A–C).
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RIF: rifampin; GC: growth control. Dashed line represents bactericidal activity that occurred at any
time point compared to the initial bacterial inoculum [17–20].
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Regarding a possible relationship between the clonality of isolates and the synergistic effect of
different combinations against CR-Ab, we could say that no synergism was observed for clone A
whereas all the tested combinations were synergic towards clone C. MEM + TIG was mostly in-vitro
effective against strains belonging to Clone B (3/4, 75%) whereas e un-conventional regimen COL +
RIF represented the most synergic combination towards clones D an E (2/3 each, 66%).
3. Discussion
Infections caused by CR-Ab represe t a major halle ge for physicians due to the high morbidity
and mortali y rates [1]. In particular, the growing levels of r sistance even to COL, which has been
considered as the last resort drug, is particularly worrying due to the already limited therapeutic
options available [21]. In this critical scenario, researchers focused their attention on non-conventional
antimicrobial combinations (i.e., COL plus antimicrobials active only against Gram-positives) [11,12]
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as well as on non-antimicrobial compounds exhibiting antibacterial properties, such as phages or
essential oils [22].
With regard to non-conventional antimicrobial combinations, COL + VAN or COL + RIF gained
interest given the high activity in-vitro as well as in animal models [23,24] or even in clinical
studies [14,25–27]. While there is concern regarding the possible augmented risk of nephrotoxicity
with the combination COL + VAN [26], the association COL + RIF showed a higher microbiological
eradication rate than COL alone, although not influencing the overall mortality compared to COL
monotherapy [14]. From a clinical point of view, a recent randomized clinical trial suggested no
advantages of COL + MEM combination versus COL monotherapy for severe CR-Ab infections;
however, from a microbiological standpoint, the possibility of evinced resistance to COL during
monotherapy is a matter of debate and should be taken into account when considering the optimal
regimen (monotherapy versus combination therapy) against CR-Ab [13,28].
In the present study, the aim was to investigate on the in-vitro synergistic and bactericidal activity
of different antimicrobial combinations (with and without COL) against strains of CR-Ab isolated
from patients with CR-Ab infections whose clinical data were also presented. Herein, it has been
demonstrated that a combination consisting of COL + VAN or COL + RIF was effective against CR-Ab
and might represent a valid therapeutic option for severe infections caused by MDR A. baumannii.
Interestingly, the results of killing studies showed that these combinations were highly effective
even in the presence of COL resistance. This finding is in line with previous in-vitro studies that
evaluated different combinations against COL-resistant strains and found that COL associated with
RIF was the most synergistic one [29–34]. However, the strength of the present study resides on
the evaluation of the synergistic effect of the tested combinations, including COL + VAN, by killing
studies rather than other methods, thus giving additional information on the kinetic for obtaining the
bactericidal and synergistic activity. In fact, it is herein shown that the bactericidal effect of COL + RIF
and COL + VAN occurred early, after 2–4 h of incubation, in the absence of bacterial growth for up to
24 h. The rationale of using COL + VAN or RIF relies on COL cell-permeabilizing properties, which
might allow associated drug to reach its target at sub-inhibitory concentrations [10,35,36].
Apart from in-vitro results, the clinical experience on the use of these regimens against
COL-resistant CR-Ab is still low [15,37]. Thus, in addition to microbiological analyses, in the present
report clinical data of patients infected with CR-Ab are also presented, including subjects with
infections due to COL-resistant strains who received treatment based on COL + VAN or COL +
RIF combinations. Herein, the overall mortality was low and did not differ between patients treated
with COL + VAN, COL + RIF or other COL-based combinations, with absence of nephrotoxicity in
patients receiving COL + VAN.
A further strength of the study is the investigation of combinations not containing COL, such
as MEM + TIG; in fact, this combination could still retain a place in therapy when the use of COL is
contraindicated or the risk of COL pharmacokinetic under exposure is a matter of concern [16]. Overall,
we found a rate of synergy slightly higher than that found in previous studies by the checkerboard
method (36% vs. 20%), which was most prominent in COL sensitive strains [15,38]. In the killing
studies, although MEM + TIG was in-vitro effective against COL-sensitive strain, in the presence of
low-level of COL resistance the bactericidal activity, although still present, occurred only after 24 h
and, in the presence of high-level of COL resistance, the activity was completely absent. The latter is
of particular importance due to main points: i) in the presence of kidney failure or other side effects
related to the use of COL, MEM + TIG combination might be considered a better option to treat COL
susceptible CR-Ab strains whereas in the presence of high COL resistance this combination may not be
effective; ii). The presence of COL resistance represents a condition which might make the isolates
more susceptible to COL-containing regimens, probably as a consequence of the alterations in the outer
membrane and lipopolysaccharide (LPS) that confer COL resistance, thus raising the vulnerability of
CR-Ab to these combinations [39]. However, a definite conclusion on the therapeutic role of MEM +
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TIG combination in the presence of COL-resistance cannot be deduced with certainty due to the low
number of COL-resistant strains tested.
With regard to the results of PFGE analyses, it was shown that clone B was the most common and
exclusively found in one specific ward, whereas clone C belonged to a strain not primarily circulating
at SUR hospital. On the other hand, the diffusion of clones A, D and E in wards not related to each
other suggests that multiple clones of CR-Ab are simultaneously present in the hospital. In an attempt
to evaluate whether the synergistic effect against CR-Ab was related to the clonality of the isolates, we
found that all the tested combinations did not show the same synergistic effect against different clones
of CR-Ab, with some apparently more effective than others towards a specific clone. However, given
the paucity of tested strains, a definite conclusion on the potential role of clonality on determining the
synergistic effect of different combinations cannot be drawn [15].
4. Materials and Methods
4.1. Bacterial Strains and Clinical Data Collection
A series of CR-Ab collected from patients hospitalized at Sapienza University of Rome (SUR)
was included in the study. Clinical samples underwent traditional microbiological procedures as for
daily practice, with the use of the VITEK-2 (Bio-Merieux, Marcy l’Etoile, France) automated system for
identification and antimicrobial susceptibility testing. Until further microbiological analyses, bacteria
were stored on cryovial bead preservation system (Microbank; Pro-Lab Diagnostics, Richmond Hill,
Ontario, Canada) at −80 ◦C. Overnight cultures were then adjusted to a turbidity of 0.5 McFarland,
corresponding to ≈1 × 108 CFU/mL. For each patient clinical and demographic data were collected.
Type of infection was defined in accordance to Centres for Disease Control and Prevention (CDC)
guidelines [40]. Clinical cure was defined as resolution of CR-Ab infection. Data collection and
microbiological analysis were anonymously and confidentially performed and approved by the Ethics
Committee of Policlinico Umberto I of Rome. All experiments were performed in accordance with
guidelines and regulations, following the rules of the Declaration of Helsinki.
4.2. Antimicrobial Agents
Antimicrobial agents were provided as purified powders by the manufacturer (Sigma Aldrich,
Milan, Italy). Stock solutions at different concentrations were prepared in sterile and pyrogen-free
0.9% saline or water, according to manufacturer’s instructions.
4.3. Molecular Typing by Pulsed-Field Gel Electrophoresis (PFGE)
The preparation of genomic DNA of CR-Ab isolates was performed as previously described [41].
DNA restriction was done with ApaI enzyme (New England Biolabs, Ipswich, MA, USA) at 25 ◦C
for 4 h. The gels were run on a CHEF-DRII system (Bio-Rad Laboratories, Hercules, CA, USA) over
20 h at 14 ◦C with 5 to 13 s of linear ramping at 200 V. It was assumed that a single base mutation in
the chromosomal DNA could introduce at most a 3-fragment difference in the restriction pattern [42];
isolates with more than 3 fragment variations were assumed to represent strains with major patterns
(assignment of capital letters), while isolates with 1–3 fragment differences were considered subtypes
(capital letters with numerical subscripts).
4.4. Antimicrobial Evaluation
Minimal inhibitory concentrations (MICs) of MEM, COL, RIF, tigecycline (TIG) and VAN
were determined by macro broth dilution (MBD) method in cation-adjusted Mueller Hinton broth
(CA-MHB) [43]. Briefly, two-fold serial dilutions of each antimicrobial agent were prepared in 2
mL CA-MHB in borosilicate glass tubes and incubated for 24 h at 37 ◦C. MIC was defined as the
lowest concentration of antibiotic that completely inhibited visible growth. In addition, for COL and
TIG a gradient strip MIC determination (E-test) was performed. For synergistic activity evaluation,
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checkerboard method of the following antimicrobial combinations was performed: COL + MEM,
COL + RIF, COL + TIG, COL + VAN, MEM + TIG. A 96-well microtiter plate containing antibiotic
combinations at different concentrations was used to perform checkerboard synergy testing. Wells
containing a final inoculum of ~5 × 105 CFU/mL were incubated at 37 ◦C for 24 h under static
conditions in CA-MHB. The fractional inhibitory concentration index (FICI) of each combination was
defined as: ∑FIC: FICA + FICB = MICA + B/MICAalone + MICB + A/MICBalone. Synergism was
defined as FICI ≤ 0.5 whereas FICI > 0.5 but <4 were considered as indifferent or non-antagonistic [44].
In addition, killing studies of different antimicrobial combinations were performed on 3 representative
strains, according to COL sensitivity [one strain with full COL susceptibility (COL-S); one strain with
low-level of COL resistance (COL- LR); one strain with high-level of COL resistance (COL-HR)]. COL
susceptibility or resistance was defined in accordance to the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) clinical breakpoint [18,19]. The following concentrations were used
for killing tests: 1 × MIC COL, 0.5 × MIC RIF, 0.5 × MIC MEM, 0.5 × MIC TIG, VAN, 1 × MIC
COL + VAN, 1 × MIC COL + 0.5 × MIC TIG, 1 × MIC COL + 0.5 × MIC RIF, 1 × MIC COL + 0.5
× MIC MEM, 0.5 × MIC MEM + 0.5 × MIC TIG, 1 × MIC MEM + 1 × MIC TIG. The tested VAN
concentration was fixed at 16 mg/L, which reflects the serum achievable concentration during VAN
therapy [25]. Bactericidal activity was defined as ≥99.9% (i.e., ≥ 3-log10 CFU/mL) reduction of the
initial bacterial count at each time point. Synergy was defined as a ≥100-fold decrease in CFU/mL
between the combination and its most active constituent at the same concentration after 24 h, with the
number of surviving organisms in the presence of the combination ≥ 100-fold CFU/mL below the
starting inoculum. The MIC values used for synergy testing were those obtained throughout MBD. All
in-vitro experiments were performed in triplicate.
5. Conclusions
In conclusion, it is herein demonstrated that combinations of COL with VAN or RIF were highly
synergic and rapidly bactericidal against CR-Ab, including COL-resistant strains and that, in the
presence of kidney failure or other side effects related to the use of COL, MEM + TIG might be
considered a reasonable approach to treat mainly COL susceptible CR-Ab strains.
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